Intrinsic Imaging Awarded Phase II Clinical Trial to Assess New Treatment for Non-Hodgkins Lymphoma

Imaging core lab services and PET/CT or PET/MRI review for an international Phase II trial of a non-Hodgkin lymphoma treatment.

Bolton, MA / San Antonio, TX

Bolton, MA / San Antonio, TX — August 29, 2014 — Intrinsic Imaging, an FDA audited, ISO 9001:2008 and ISO 13485:2003 certified, GAMP® 5 compliant imaging core lab, announced today that it has been awarded an international Phase II clinical trial to assess a new treatment for patients with non-Hodgkins lymphoma.

Throughout this trial, Intrinsic Imaging will provide comprehensive imaging core lab services including, but not limited to, protocol and charter development, site qualification, site training and management, image transfer, blinding and processing as well as the specialized radiologic review of images acquired using positron emission tomography coupled with computed tomography (PET/CT), or PET coupled with magnetic resonance imaging (PET/MRI).

Intrinsic Imaging's more than sixty board-certified radiologists have fellowship training in all subspecialty therapeutic areas including Oncology. The Oncology team consists of 12 full-time board-certified, fellowship trained radiologists all of whom have significant expertise in the evaluation of many cancers including but not limited to breast, cervical, colorectal, gastric, head and neck, lung, lymphoma, melanoma, ovarian, prostate, renal and thyroid.

"At Intrinsic Imaging, we are able to provide our wealth of oncology expertise to the design and management of clinical trials and to the determination of drug efficacy and/or disease progression," said Todd A. Joron, BSc. MBA, President and Chief Operating Officer, Intrinsic Imaging. "Of the more than 1 million images reviewed annually by Intrinsic Imaging radiologists, 400,000 images are oncology related."

Non-Hodgkin's lymphoma is cancer that originates in the lymphatic system. According to their April 2014 report, the Leukemia and Lymphoma Society estimate there are 558,340 people in the United States who are living with the disease or are in remission and another 70,800 new cases of non-Hodgkin's lymphoma are expected to be diagnosed. Non-Hodgkin's lymphoma is the seventh most common cause of cancer related deaths in the United States.

About Intrinsic Imaging, LLC

Intrinsic Imaging is an ISO certified medical imaging CRO and imaging core lab providing comprehensive services in support of Phase I-IV clinical trials and Class I, II, III medical device trials. Intrinsic Imaging is also a world leader in conducting Artificial Intelligence studies. With its team of more than 750 board-certified and fellowship-trained physicians, Intrinsic Imaging's team has sub-specialization in all therapeutic areas, including Cardiovascular, Central Nervous System,Gastroenterology, Musculoskeletal, Oncology and Ophthalmology. Certified by the British Standards Institution (BSI), Intrinsic Imaging is the only company in the world to hold five ISO certifications specifically for providing imaging core lab services on clinical trials. For more information, please visit www.IntrinsicImaging.com.

Contact:

Intrinsic Imaging, LLC
580 Main St., Suite 210
Bolton, MA, 01740, USA
+1 978-616-4650
Contact@IntrinsicImaging.com